“If Powerful AI is directed at solving humanity’s hardest problems and the risks are managed responsibly, the potential is ...

Incyte has pointed to a spread of phase 1 data for its KRAS G12D inhibitor as proof that the company has a worthy rival to Revolution Medicines in this newly hot cancer space. | Incyte has pointed to ...

Lycia Therapeutics went public with an upsized $317.5 million IPO on Friday, while immunology-focused Windward Bio has also seen which way the public markets are blowing. | Lycia Therapeutics went ...

Boehringer Ingelheim and Microsoft have launched a collaboration to explore the use of AI-powered digital patient twins to improve clinical trial design. | Boehringer Ingelheim and Microsoft have ...